Home PR Newswire
Monday, September 7, 2026
30
C
Bengaluru
Hot topics
Creador Bets Big on Indian Pharma with 7% La Renon Stake
In a significant development for the Indian pharmaceutical industry,...
Pharma Marketing & The Reinvention
Introducing the top 10 companies in top 10 therapy areas according to statistics published by AIOCD
Mounjaro to Orforglipro: Lilly’s $6 Billion Bet on the Next GLP‑1 Revolution
Eli Lilly is in a rare position. Its GLP-1...
The Forgotten HisTORy of Surendra Nath Sehgal: Discovery of Rapamycin
From the Soil of Rapa Nui to the Brain’s...
Managing Or Gardening? Great Managers Are Like Gardeners: Cultivating Growth in Teams
A great manager is not just a leader; they...
RPG-Raghava and Lessons From a Decade of Indian Pharma M&A
RPG Active Pharma’s agreement to acquire the API and...
Pharmacy of the World Pricing Paradox
India occupies an extraordinary position in global pharmaceuticals. It...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
RPG-Raghava and Lessons From a Decade of Indian Pharma M&A
RPG Active Pharma’s agreement to acquire the API and...
Pharmacy of the World Pricing Paradox
India occupies an extraordinary position in global pharmaceuticals. It...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
RPG-Raghava and Lessons From a Decade of Indian Pharma M&A
RPG Active Pharma’s agreement to acquire the API and...
Pharmacy of the World Pricing Paradox
India occupies an extraordinary position in global pharmaceuticals. It...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
RPG-Raghava and Lessons From a Decade of Indian Pharma M&A
RPG Active Pharma’s agreement to acquire the API and...
Pharmacy of the World Pricing Paradox
India occupies an extraordinary position in global pharmaceuticals. It...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
Hot topics
Sales Readiness For Trainers and Reps – Improve Effectiveness In A New Pharma World
Last week, I was in a meeting with the...
Talent Management
A diverse, summer issue with articles on topics ranging from content marketing to the role of experience in a VUCA world. Also, the latest book for Medical Reps reviewed by Prof. Vivek Hattangadi
Biocon’s Landmark Succession Planning: Claire Mazumdar is the Future Leader
In a landmark decision for India’s biotechnology sector, Kiran...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Indian Hospitals and Private Equity: Healthy for Patients?
If healthcare is so lucrative that global private equity...
RPG-Raghava and Lessons From a Decade of Indian Pharma M&A
RPG Active Pharma’s agreement to acquire the API and...
Pharmacy of the World Pricing Paradox
India occupies an extraordinary position in global pharmaceuticals. It...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
RPG-Raghava and Lessons From a Decade of Indian Pharma M&A
RPG Active Pharma’s agreement to acquire the API and...
Pharmacy of the World Pricing Paradox
India occupies an extraordinary position in global pharmaceuticals. It...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
RPG-Raghava and Lessons From a Decade of Indian Pharma M&A
RPG Active Pharma’s agreement to acquire the API and...
Pharmacy of the World Pricing Paradox
India occupies an extraordinary position in global pharmaceuticals. It...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
RPG-Raghava and Lessons From a Decade of Indian Pharma M&A
RPG Active Pharma’s agreement to acquire the API and...
Pharmacy of the World Pricing Paradox
India occupies an extraordinary position in global pharmaceuticals. It...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
RPG-Raghava and Lessons From a Decade of Indian Pharma M&A
RPG Active Pharma’s agreement to acquire the API and...
Pharmacy of the World Pricing Paradox
India occupies an extraordinary position in global pharmaceuticals. It...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
Newsletter
Get important news delivered directly to your inbox and stay connected!